Advertisement

Topics

Gemphire's cholesterol drug shows promise in Phase 2

05:29 EDT 29 Jun 2017 | BioPharmaDive

Gemcabene, in-licensed from Pfizer, showed strong efficacy and safety in a handful of patients with a rare genetic disorder. But questions remain about the drug's future.

Original Article: Gemphire's cholesterol drug shows promise in Phase 2

NEXT ARTICLE

More From BioPortfolio on "Gemphire's cholesterol drug shows promise in Phase 2"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...